INDOCO REMEDIES LTD

indoco remedies limited

INDOCO HOUSE, 166 C. S. T. ROAD, SANTACRUZ (EAST), MUMBAI - 400 098 (INDIA) ● Website : www.indoco.com
PHONES : (91-22) 3386 1000 / 3386 1250 ● FAX : (91-22) 2652 3067 / 2652 3976 ● CIN : L85190MH1947PLC005913

November 07, 2017

To The Listing Department **National Stock Exchange of India Limited** Exchange Plaza, Bandra - Kurla Complex Bandra (East) Mumbai - 400 051 ***Stock Code : INDOCO-EQ***	To The Listing Department **Bombay Stock Exchange Limited** Floor 25, P. J. Towers, Dalal Street, Mumbai - 400 001 ***Stock Code :* 532612**

Dear Sir,

Sub : Information to pursuant to Regulation 30 of the SEBI (LODR) Regulations,2015 (Listing Regulations)

Pursuant to Regulation 30(2) read with Schedule III Part A Para A(4)(h) of the Listing Regulations, enclosed is a press release ,inter alia covering the unaudited financial results of the Company for the quarter 30.09.2017.

Kindly note the above.

Thanking you,

Yours faithfully,
For Indoco Remedies Limited

Jayshankar Menon
Company Secretary

INDOCO REMEDIES LTD.

Indoco's Net Profit at Rs 19.76 Crores

Double Digit Growth in Domestic Business

Mumbai, November 7, 2017: Indoco Remedies posted revenues of ₹ 280.0 crores during the second quarter of FY 2017-18, as against ₹ 276.4 crores, for the same period last year. The Company's Profit After Tax is at ₹ 19.76 crores, as against ₹ 22.13 crores for the same period last year.

***Commenting on this development, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said**, "After a tumultuous first quarter in which Indian and International Businesses were severely affected, the Indian Business has recovered well with a double digit growth during the quarter. The Company will soon commence production of some of the existing ophthalmic products from Goa plant II for US market, which will help partial revival of growth of our International Formulation Business".*

For the quarter ended September'17, the financials are as under:

(₹ in Crores)

Particulars	July'17-Sept'17	July'16- Sept'16
Net Revenue	280.0	276.4
EBIDTA	40.9	42.6
Profit After Tax	19.8	22.1
EPS (Face value ₹ 2/-) (Not annualized)	2.14	2.40

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 165 million Company, employs over 6000 people, including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, MCC-South Africa, etc. Indoco develops and

manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from around 3,10,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Tuspel Plus, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit www.indoco.com

Media Inquiries:

Vilas V. Nagare
Mobile: 9820215745
E-mail: vilasn@indoco.com / corpcom@indoco.com